Stockwatch: No Second Chances For Underperforming Drug Launches
Earnings Season, Coronavirus And Debt Expose Fragile Investment Propositions
Executive Summary
As the first-quarter 2020 earnings season transitions from big pharma to the long tail of smaller biotech companies, the coronavirus pandemic-related dynamics of channel stocking and greatly diminished numbers of clinic visits have magnified effects at companies with single underperforming drugs.